APPS vs INBX
APPS: Digital Turbine provides a mobile growth platform that helps app developers, OEMs, and carriers optimize mobile app discovery, advertising, and user engagement. INBX: Inhibrx Biosciences is a clinical-stage biotechnology company leveraging advanced protein engineering to develop targeted therapeutic candidates for complex diseases.
Side-by-side fundamentals
| Metric | APPS | INBX | Edge |
|---|---|---|---|
| Price as of 2026-10-30 close | $8.87 | $71.78 | |
| Market cap | $1.1B | $1.1B | |
| Net margin | -6.7% | -10773.5% | APPS higher |
| Gross margin FY2026, SEC XBRL | +56.9% | n/a | |
| Operating margin | +6.0% | -10386.5% | APPS higher |
| ROE FY2026, SEC XBRL | -19.6% | n/a | |
| ROA | -4.5% | -95.6% | APPS higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-30 | 1.85 | n/a | |
| Revenue growth (YoY) | +15.2% | +550.0% | INBX higher |
| Revenue CAGR (3y) SEC XBRL | -5.3% | -15.0% | APPS higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 2.37 | 1.30 | |
| 1-year return as of 2026-10-30 close | +47.3% | -8.6% | APPS higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-30.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.